Genmab (GMAB) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biotech company Genmab reported impressive net sales of $3,016 million for its cancer treatment DARZALEX in the third quarter of 2024, with strong performance both in the U.S. and globally. The company benefits from royalties on these sales, which are managed through a licensing agreement with Janssen Biotech.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.